Creo Medical Group plc
("Creo" or the "Company")
Exercise of Options
Creo Medical Group plc (AIM: CREO), the medical device company, focused on the emerging field of surgical endoscopy, confirms that it has issued, conditional on admission, 49,209 new ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the exercise of share options. It is expected that admission of the Ordinary Shares will occur at 8:00 a.m. on 23 April 2021.
Following admission, the Company will have 157,940,390 Ordinary Shares in issue. This figure of 157,940,390 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Enquires:
| Creo Medical Group plc | |
| Richard Rees (CFO) | +44 (0)1291 606 005 |
|
|
|
| Cenkos Securities plc | +44 (0)20 7397 8900 |
| Stephen Keys / Camilla Hume (NOMAD) |
|
| Michael Johnson / Russell Kerr (Sales) |
|
|
|
|
| Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
| Paul McManus / Lianne Cawthorne | Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 |
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA Advanced Energy Platform powered by its unique full spectrum Kamaptive Technology to market, enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment. An overview of the Creo Medical device technology portfolio can be seen here:
https://www.rns-pdf.londonstockexchange.com/rns/8918P_1-2020-6-14.pdf
For more information about Creo Medical please see our website, www.creomedical.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
